Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06133816 · ClinicalTrials.gov registry record · NA
Lung Cancer Screening Eligibility Assessment
A NA study, sponsored by Abramson Cancer Center at Penn Medicine.
- Completed
- Registry status
- NA
- Development phase
- 6,125
- Enrollment target
NCT06133816 is a NA study that has completed, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 6,125 participants.
The verdict
NCT06133816, a NA study, has completed, sponsored by Abramson Cancer Center at Penn Medicine.
- COMPLETED
- Registry status
- NA
- Development phase
- 6,125 participants
- Enrollment target
Study Summary
The primary purpose of this study evaluate if different messaging impacts response rates to a brief survey (i.e., the simplified eligibility tool) that is designed to estimate pack-year eligibility for lung cancer screening (LCS). This will help inform the best way to increase response rates to the tool in future intervention studies designed to increase LCS, and expand upon survey methodology in general.
Interventions
- BEHAVIORAL Framed Introductory Message A
- BEHAVIORAL Framed Introductory Message B
- BEHAVIORAL Framed Introductory Message C
- BEHAVIORAL Framed Tobacco Use Message A
- BEHAVIORAL Framed Tobacco Use Message B
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6,125 participants |
| Start Date | 2023-07-31 |
| Est. Completion | 2024-01-31 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06133816
The ClinicalTrials.gov registry entry for NCT06133816 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 6,125 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abramson Cancer Center at Penn Medicine, which has 402 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Framed Introductory Message A is the first listed.
NCT06133816 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06133816 about?
NCT06133816 is a clinical study titled "Lung Cancer Screening Eligibility Assessment". The primary purpose of this study evaluate if different messaging impacts response rates to a brief survey (i.e., the simplified eligibility tool) that is designed to estimate pack-year eligibility for lung cancer screening (LCS). This will help inform the best way to increase response rates to the ...
What is the current status of trial NCT06133816?
This trial is currently completed. It is a NA study. The enrollment target is 6,125 participants. The study started on 2023-07-31. Estimated completion is 2024-01-31.
What interventions are being tested in trial NCT06133816?
The interventions under investigation include: Framed Introductory Message A (BEHAVIORAL), Framed Introductory Message B (BEHAVIORAL), Framed Introductory Message C (BEHAVIORAL), Framed Tobacco Use Message A (BEHAVIORAL), Framed Tobacco Use Message B (BEHAVIORAL).
Who is sponsoring clinical trial NCT06133816?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.